{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(1)"],"submitter":["Ding J"],"pubmed_abstract":["The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer."],"journal":["Experimental hematology & oncology"],"pagination":["59"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9494903"],"repository":["biostudies-literature"],"pubmed_title":["Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer."],"pmcid":["PMC9494903"],"pubmed_authors":["Liu X","Hei H","Li D","Sun B","Zhou D","Ding J","Zhou K","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer.","description":"The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-26T12:00:05.613Z","creation":"2025-04-06T13:49:47.239Z"},"accession":"S-EPMC9494903","cross_references":{"pubmed":["36138444"],"doi":["10.1186/s40164-022-00311-z"]}}